2010-02-04 16:14:07 -

Research and Markets ( www.researchandmarkets.com/research/283288/brief_report_inte : ) has announced the addition of the " Brief Report: Interleukin-17 (IL-17R) and IL-17 Receptor Antagonists : " report to their offering.

The present Brief Report about molecules targeting interleukin-17 (IL-17) or its receptor provides an assessment, competitor evaluation and detailed profiles of antibodies and other molecules in development.
R&D projects of primarily antibodies targeting IL-17 or IL-17R to treat inflammatory and autoimmune diseases are discussed as of February 2010.
A total of three different antibodies are in mid- and late stage clinical development, with others in early clinical, non-clinical or preclinical phases of development.

The IL-17 family consists of six ligands, A-F. IL-17 was originally thought to signal via the classic receptor IL-17R,

but IL17 stimulates a receptor complex that consists of the subunits IL-17RA and IL-17RC. In 2005, a distinct subset of pro-inflammatory T cells (called type 17 T-helper (TH17) cells) were discovered that serve as a major source of IL-17. Thus, the TH17 cell and the powerful inflammatory cytokine IL-17 have become a major target in autoimmune disease. The IL-17 family has been linked to many immune/autoimmune related diseases including rheumatoid arthritis, psoriasis, asthma, inflammatory bowel diseases and multiple sclerosis. First clinical Proof-of-Concept studies indicate a rapid onset of action and maintained anti-inflammatory activity without serious side effects which might differentiate it from anti-IL-23/12 antibodies. Quite a number of anti-IL17R molecules are clinical development although target validation was achieved only recently with potential implications for the intellectual property position.

This brief report with 42 pages describes the background of the target and the scientific rationale to develop molecules targeting IL-17 or IL17R. Sub-targets of IL-17 and IL-17R are discussed. An overview of patent filings is given. The status of clinical and preclinical R&D is described and critically assessed. Individual profiles of the IL-17/R antagonists already in clinical development and in preclinical research are presented in detailed textual description and in an tabulated executive summary with references. The Brief Report also includes a summary list of the target pipeline with other research projects.


Key Topics Covered:

- Target Background;
- Scientific Rationale;
- Clinical Indications
- Patents
- Status of Development and Assessment
- Individual Project Profiles
- Target Pipeline Summary


The Target Pipeline Summary provides information in a tabular format for.

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Product Category,
- Company,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

For more information visit www.researchandmarkets.com/research/283288/brief_report_inte :



Research and MarketsLaura Wood, Senior Manager, press@researchandmarkets.com : mailto:press@researchandmarkets.com U.S.

Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716